IN8bio (INAB) News Today $2.21 -0.05 (-2.21%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.22 +0.00 (+0.23%) As of 08/29/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INAB Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period In8bio, Inc. Reports Improved Financial PerformanceAugust 18, 2025 | theglobeandmail.comIN8bio (INAB) Q2 Loss Narrows 77%August 18, 2025 | theglobeandmail.comIN8bio Reports Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 7, 2025 | globenewswire.comIN8bio, Inc. (INAB) stock price, news, quote & history – Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comIN8bio Regains Nasdaq Compliance with Bid Price RuleJune 30, 2025 | tipranks.comIN8bio, Inc: IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma TrialJune 9, 2025 | finanznachrichten.deIN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma TrialJune 9, 2025 | globenewswire.comIN8bio (NASDAQ:INAB) Stock Rating Upgraded by Wall Street ZenJune 7, 2025 | marketbeat.comIN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free SurvivalJune 2, 2025 | globenewswire.comIN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025May 14, 2025 | globenewswire.comIN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical ProductsMay 12, 2025 | globenewswire.comIN8bio Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 7, 2025 | globenewswire.comIN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific ConferencesApril 29, 2025 | globenewswire.comIN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025April 28, 2025 | globenewswire.comIN8bio to Present New Preclinical Data on Novel Gamma-Delta (?d) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025March 31, 2025 | tmcnet.comIN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025March 31, 2025 | globenewswire.comIN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025March 18, 2025 | globenewswire.comINAB: Introducing INB-600, A γδ T Cell Engager PlatformMarch 17, 2025 | msn.comIN8bio Reports Strong Clinical Progress and Expands Pipeline with Innovative Gamma-Delta T Cell TherapiesMarch 15, 2025 | nasdaq.comIN8BIO Earnings Results: $INAB Reports Quarterly EarningsMarch 15, 2025 | nasdaq.comIN8bio, Inc: IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business HighlightsMarch 14, 2025 | finanznachrichten.deIN8bio price target lowered to $6 from $8 at H.C. WainwrightMarch 14, 2025 | markets.businessinsider.comIN8bio reports Q4 EPS (8c), consensus (8c)March 13, 2025 | markets.businessinsider.comIN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business HighlightsMarch 13, 2025 | globenewswire.comIN8bio announces board member resignationMarch 7, 2025 | uk.investing.comIN8bio, Inc: IN8bio Announces Advanced Gamma-Delta T cell Engager (TCE) Platform for Oncology and Autoimmune DiseasesMarch 3, 2025 | finanznachrichten.deIN8bio announces gamma-delta T cell enager platformMarch 3, 2025 | markets.businessinsider.comIN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune DiseasesMarch 3, 2025 | globenewswire.comIN8bio to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 26, 2025 | globenewswire.comIN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual ConferenceFebruary 24, 2025 | globenewswire.comINAB: Continued Survival in INB-100 TrialFebruary 19, 2025 | finance.yahoo.comIN8bio Inc Ordinary SharesFebruary 14, 2025 | morningstar.comMIN8bio reports promising phase 1 results for leukemia therapyFebruary 14, 2025 | msn.comIN8bio presented Phase 1 data on INB-100 at 2025 TCTFebruary 14, 2025 | markets.businessinsider.comIN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AMLFebruary 14, 2025 | globenewswire.comJones Trading Upgrades IN8bio (INAB)February 12, 2025 | msn.comThis MIcro Cap Found Mid-Week Success On New Clinical DataFebruary 11, 2025 | msn.comIN8bio reports updated results from Phase 1 trial of INB-100February 11, 2025 | markets.businessinsider.comJones Trading lifts IN8bio stock rating to Buy, sets $1.20 targetFebruary 11, 2025 | msn.comMizuho Securities Keeps Their Buy Rating on IN8bio (INAB)February 11, 2025 | markets.businessinsider.comIN8bio, Inc: IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia PatientsFebruary 11, 2025 | finanznachrichten.deINB-100 shows promise in AML patient remission ratesFebruary 11, 2025 | msn.comIN8bio upgraded to Buy from Hold at JonesResearchFebruary 11, 2025 | markets.businessinsider.comJonesResearch upgrades IN8bio to Buy on ‘impressive’ AML dataFebruary 11, 2025 | markets.businessinsider.comIN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia PatientsFebruary 11, 2025 | globenewswire.comIN8bio gains extension to meet Nasdaq listing requirementsFebruary 8, 2025 | msn.comIN8bio to Present at Biotech Showcase 2025 in San FranciscoJanuary 6, 2025 | finance.yahoo.comIN8bio announces updated data for Phase 1 trial of INB-100December 11, 2024 | markets.businessinsider.comIN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual MeetingDecember 10, 2024 | globenewswire.comMizuho Securities Remains a Buy on IN8bio (INAB)November 27, 2024 | markets.businessinsider.com Get IN8bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INAB Media Mentions By Week INAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INAB News Sentiment▼1.881.09▲Average Medical News Sentiment INAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INAB Articles This Week▼11▲INAB Articles Average Week Get the Latest News and Ratings for INAB and Related Stocks Enter your email address to receive the latest news and analysts' ratings for IN8bio and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies PYRGF News Today LVTX News Today MDCX News Today CALC News Today MRSN News Today XCUR News Today OKUR News Today RVPH News Today XLO News Today MURA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INAB) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IN8bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IN8bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INAB Stock Alerts